Antimicrobial Coverage and Dosing for Mixed Community-Acquired Infections

Antimicrobial Spectrum and Efficacy

The combination of ampicillin-sulbactam and ciprofloxacin provides comprehensive coverage for mixed community-acquired infections, targeting gram-positive cocci, enteric gram-negative organisms, anaerobes, and resistant gram-negative rods, as recommended by the Infectious Diseases Society of America 1
Ampicillin-sulbactam has intrinsic activity against Acinetobacter baumannii at MIC ≤4 mg/L, according to the European Society of Clinical Microbiology and Infectious Diseases 2, 3
The American College of Clinical Pharmacy recommends ciprofloxacin for its excellent activity against resistant gram-negative organisms, including Pseudomonas aeruginosa, although the specific recommendation is not provided in the given text 1

The standard dosing for ampicillin-sulbactam is 1.5–3 g IV every 6–8 hours, as recommended by the Clinical Infectious Diseases society 1, 4
For severe infections, such as those caused by Acinetobacter, the recommended dosing is 9–12 g/day of sulbactam component in 3 divided doses, according to the Intensive Care Medicine society 2, 3, 5
The Infectious Diseases Society of America recommends ciprofloxacin 400 mg IV every 12 hours for normal renal function 1, 4
The American Urological Association recommends ciprofloxacin 500 mg PO every 12 hours for normal renal function 6

The Infectious Diseases Society of America warns against using ampicillin-sulbactam for empiric community-acquired intra-abdominal infections due to high rates of E. coli resistance 7
The European Association of Urology recommends avoiding ciprofloxacin empirically if local resistance rates exceed 10%, or in patients who received fluoroquinolones within the last 6 months 8
The combination of ampicillin-sulbactam, clindamycin, and ciprofloxacin provides optimal coverage against the polymicrobial nature of necrotizing fasciitis and mixed infections, including resistant gram-negative rods, anaerobes, and gram-positive cocci, as recommended by the Clinical Infectious Diseases society 1, 4